➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Harvard Business School
AstraZeneca
Johnson and Johnson
McKinsey

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

BAQSIMI Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Baqsimi patents expire, and when can generic versions of Baqsimi launch?

Baqsimi is a drug marketed by Eli Lilly And Co and is included in one NDA. There are four patents protecting this drug.

This drug has sixty-one patent family members in thirty-seven countries.

The generic ingredient in BAQSIMI is glucagon. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glucagon profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Baqsimi

A generic version of BAQSIMI was approved as glucagon by LILLY on September 11th, 1998.

  Get Started Free

US Patents and Regulatory Information for BAQSIMI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for BAQSIMI

Country Patent Number Estimated Expiration
European Patent Office 1339501   Get Started Free
China 109070121   Get Started Free
European Patent Office 3673900   Get Started Free
World Intellectual Property Organization (WIPO) 0245866   Get Started Free
El Salvador 2017005515   Get Started Free
Guatemala 201700179   Get Started Free
Japan 2018507852   Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
McKinsey
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.